Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer

被引:177
作者
Boland, Genevieve M. [1 ]
Chang, George J. [1 ]
Haynes, Alex B. [1 ]
Chiang, Yi-Ju [1 ,2 ]
Chagpar, Ryaz [3 ]
Xing, Yan [1 ]
Hu, Chung-Yuan [1 ]
Feig, Barry W. [1 ]
You, Y. Nancy [1 ]
Cormier, Janice N. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Inst Canc Care Excellence, Houston, TX 77030 USA
[3] Univ Western Ontario, Div Gen Surg, London, ON, Canada
基金
美国国家卫生研究院;
关键词
outcome assessment; colonic neoplasms; standards; survival analysis; multivariate analysis; health care disparities; SURGICAL ADJUVANT BREAST; STAGE-II; COLORECTAL-CANCER; PHASE-III; DATA-BASE; RACIAL DISPARITIES; PROPENSITY-SCORE; CHEMOTHERAPY USE; POOLED ANALYSIS; FLUOROURACIL;
D O I
10.1002/cncr.27935
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: The objective of the current study was to examine the impact of adherence to guidelines on stage-specific survival outcomes in patients with stage III and high-risk stage II colon cancer. The National Comprehensive Cancer Network (NCCN) has established working, expert consensus, and evidence-based guidelines for organ-specific cancer care, including care of patients with colon cancer. METHODS: Patients who were diagnosed with colon adenocarcinoma between 1998 and 2002 were selected from within the National Cancer Data Base. The cohort was limited to patients who received their first course of treatment at the reporting facility. Pathologic variables, including tumor depth, lymph node status, and evidence of metastatic disease, were used to restage patients, and the patients were divided into low-risk and high-risk categories on the basis of criteria defined by the NCCN. Relative survival rates were calculated for the entire cohort, stratified according to adherence versus nonadherence to NCCN treatment guidelines. RESULTS: In univariate analysis of treatment adherence patterns for both patient subgroups (high-risk stage II and stage III), several factors were associated with a higher rate of nonadherence in both groups, including older age (P < .001); Medicaid, Medicare, or uninsured status versus private insurance (P < .001); and subsequent treatment at a facility other than the facility at which the cancer was first diagnosed (P < .001). In multivariate analysis, multiple factors were associated with differences in relative survival, although analyses that included the year of diagnosis did not demonstrate significant differences over time. CONCLUSIONS: The current study documented practice patterns in a heterogeneous population of patients with colon cancer and demonstrated a survival benefit for patients with stage III and high-risk stage II colon cancer who received treatment that adhered to NCCN guidelines. These data validate the current NCCN practice guidelines for colon cancer and support the concept of guideline-based metrics that can be compared across institutions to assess the quality of cancer care and to compare the quality of cancer care among institutions. Cancer 2013. (c) 2012 American Cancer Society.
引用
收藏
页码:1593 / 1601
页数:9
相关论文
共 41 条
[1]   Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[2]   Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial [J].
Andre, Thierry ;
Boni, Corrado ;
Navarro, Matilde ;
Tabernero, Josep ;
Hickish, Tamas ;
Topham, Clare ;
Bonetti, Andrea ;
Clingan, Philip ;
Bridgewater, John ;
Rivera, Fernando ;
de Gramont, Aimery .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) :3109-3116
[3]  
[Anonymous], NCCN Clinical Practice Guidelines in Oncology - Breast Cancer
[4]  
[Anonymous], SURV EP END RES SEER
[5]   American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer [J].
Benson, AB ;
Schrag, D ;
Somerfield, MR ;
Cohen, AM ;
Figueredo, AT ;
Flynn, PJ ;
Krzyzanowska, MK ;
Maroun, J ;
McAllister, P ;
Van Cutsem, E ;
Brouwers, M ;
Charette, M ;
Haller, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3408-3419
[6]   A Black-White Comparison of the Quality of Stage-Specific Colon Cancer Treatment [J].
Berry, Jamillah ;
Caplan, Lee ;
Davis, Sharon ;
Minor, Patrick ;
Counts-Spriggs, Margaret ;
Glover, Roni ;
Ogunlade, Vickie ;
Bumpers, Kevin ;
Kauh, John ;
Brawley, Otis W. ;
Flowers, Christopher .
CANCER, 2010, 116 (03) :713-722
[7]   The National Cancer Data Base: A powerful initiative to improve cancer care in the United States [J].
Bilimoria, Karl Y. ;
Stewart, Andrew K. ;
Winchester, David P. ;
Ko, Clifford Y. .
ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (03) :683-690
[8]   Adherence to Stage-Specific Treatment Guidelines for Patients With Colon Cancer [J].
Chagpar, Ryaz ;
Xing, Yan ;
Chiang, Yi-Ju ;
Feig, Barry W. ;
Chang, George J. ;
You, Y. Nancy ;
Cormier, Janice N. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (09) :972-979
[9]   Regression models for relative survival [J].
Dickman, PW ;
Sloggett, A ;
Hills, M ;
Hakulinen, T .
STATISTICS IN MEDICINE, 2004, 23 (01) :51-64
[10]   Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer [J].
Erlichman, C ;
O'Connell, M ;
Kahn, M ;
Marsoni, S ;
Torri, V ;
Tardio, B ;
Zaniboni, A ;
Pancera, G ;
Martignoni, G ;
Labianca, R ;
Barni, A ;
Seitz, JF ;
Milan, C ;
Bedenne, L ;
Giovannini, M ;
Letreut, YP ;
Skillings, J ;
Shepard, L ;
Zee, B ;
Petrioli, R ;
Francini, G .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) :1356-1363